AC Immune Past Earnings Performance
Past criteria checks 0/6
AC Immune's earnings have been declining at an average annual rate of -20.2%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 52.3% per year.
Key information
-20.2%
Earnings growth rate
-17.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -52.3% |
| Return on equity | -30.6% |
| Net Margin | -97.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Revenue & Expenses Breakdown
How AC Immune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 41 | -40 | 17 | 0 |
| 30 Jun 24 | 15 | -61 | 17 | 0 |
| 31 Mar 24 | 15 | -55 | 16 | 0 |
| 31 Dec 23 | 15 | -54 | 15 | 0 |
| 30 Sep 23 | 0 | -68 | 15 | 0 |
| 30 Jun 23 | 4 | -67 | 15 | 0 |
| 31 Mar 23 | 4 | -69 | 16 | 0 |
| 31 Dec 22 | 4 | -71 | 16 | 0 |
| 30 Sep 22 | 4 | -73 | 14 | 0 |
| 30 Jun 22 | 0 | -76 | 16 | 0 |
| 31 Mar 22 | 0 | -75 | 17 | 0 |
| 31 Dec 21 | 0 | -73 | 18 | 0 |
| 30 Sep 21 | 1 | -71 | 19 | 0 |
| 30 Jun 21 | 2 | -74 | 19 | 0 |
| 31 Mar 21 | 3 | -71 | 18 | 0 |
| 31 Dec 20 | 15 | -62 | 19 | 0 |
| 30 Sep 20 | 15 | -62 | 19 | 0 |
| 30 Jun 20 | 47 | -25 | 18 | 0 |
| 31 Mar 20 | 48 | -26 | 17 | 0 |
| 31 Dec 19 | 110 | 45 | 16 | 0 |
| 30 Sep 19 | 111 | 50 | 15 | 0 |
| 30 Jun 19 | 80 | 18 | 14 | 0 |
| 31 Mar 19 | 81 | 24 | 13 | 0 |
| 31 Dec 18 | 7 | -51 | 12 | 0 |
| 30 Sep 18 | 22 | -32 | 12 | 0 |
| 30 Jun 18 | 21 | -27 | 11 | 0 |
| 31 Mar 18 | 20 | -29 | 10 | 0 |
| 31 Dec 17 | 20 | -26 | 10 | 0 |
| 30 Sep 17 | 5 | -35 | 10 | 0 |
| 30 Jun 17 | 6 | -36 | 10 | 0 |
| 31 Mar 17 | 25 | -10 | 9 | 0 |
| 31 Dec 16 | 23 | -7 | 8 | 0 |
| 30 Sep 16 | 22 | -8 | 5 | 0 |
| 30 Jun 16 | 45 | 21 | 4 | 0 |
| 31 Mar 16 | 39 | 17 | 4 | 0 |
| 31 Dec 15 | 39 | 20 | 3 | 0 |
| 30 Sep 15 | 65 | 46 | 4 | 0 |
| 30 Jun 15 | 41 | 21 | 4 | 0 |
| 31 Mar 15 | 28 | 10 | 3 | 0 |
| 31 Dec 14 | 30 | 11 | 3 | 0 |
| 31 Dec 13 | 9 | -11 | 3 | 0 |
Quality Earnings: ACIU is currently unprofitable.
Growing Profit Margin: ACIU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACIU is unprofitable, and losses have increased over the past 5 years at a rate of 20.2% per year.
Accelerating Growth: Unable to compare ACIU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACIU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ACIU has a negative Return on Equity (-30.63%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 12:22 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AC Immune SA is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Alethia Young | Credit Suisse |
| Andrew Fein | H.C. Wainwright & Co. |